Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction CONCLUSIONS: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. N Engl J Med 2019; 381:1995-2008 https://www.nejm.org/doi/10.1056/NE Visual Abstract by Dr. Kosalan Akilan #Dapagliflozin #hfref #chf #visualabstract #ebm
